Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
Search
Close this search box.
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • CIRM Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
Menu
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • CIRM Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

Angiocrine Bioscience, Inc.

Return to Grants

Total Awards:
4
Award Value:
$25,919,710
Institution type:
For profit
Short Name:
Angiocrine

Awards to the Institution

Program Type Investigator Grant Title Award Value
Clinical Trial Stage Projects Dr. Paul Finnegan AB-205-301 Phase 3 Trial and Related Activities to Support Clinical Development of AB-205 $10,930,014
Clinical Trial Stage Projects Dr. Edward Kavalerchik AB-205-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-205 $6,192,579
Clinical Trial Stage Projects Dr. Edward Kavalerchik AB-110-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-110 $5,000,000
Late Stage Preclinical Projects Dr. Paul W Finnegan Development of AB-110: genetically-modified endothelial cells plus expanded cord blood hematopoietic stem cells as a transplantation therapy $3,797,117
Total:
$25,919,710.00
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us